ANN CLIN LAB SCI 润色咨询

ANNALS OF CLINICAL AND LABORATORY SCIENCE

出版年份：1973 年文章数：2626 投稿命中率： 开通期刊会员，数据随心看

出版周期：Quarterly 自引率：2.3% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2269047, encodeId=1f75226904e6e, content=邮箱投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:45:59 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2269044, encodeId=56052269044a8, content=40美元审稿费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:20:30 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801294, encodeId=4aaa80129474, content=投了三个多月，中间催了两次，说在under review，现在仍然没有消息，这是什么鬼啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 05 10:55:30 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121989, encodeId=04fe21219896b, content=这个杂志的文章怎么都没有doi啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d02d8107809, createdName=ms9000000001550341, createdTime=Sun Mar 26 23:07:49 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2110877, encodeId=b1dc21108e700, content=这个杂志的投稿链接是哪里啊？找半天找不到。。。，有哪位大神知道，指点指点一下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70614861774, createdName=shengbin117, createdTime=Thu Jan 19 19:38:39 CST 2023, time=2023-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1220227, encodeId=7e7d122022e64, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：免疫;肿瘤;基础<br>经验分享：已投被拒，建议投更专业的杂志，婉拒吧，挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Tue May 17 09:54:10 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588195, encodeId=bd50588195c8, content=说研究内容陈旧，前言里有一句话说法是错的，感觉审稿人很不正规。但是人家的退稿意见倒是做成很正式的感觉:官方的logo，还做成像一封信的样子的附件。。。我是该高兴呢，还是高兴呢？<span class="quote">海上飘星 2020-03-16 00:00:00 发表:<br>有什么审稿意见吗？谢谢。</span>, beContent=海上飘星 2020-03-16 00:00:00 发表: 有什么审稿意见吗？谢谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230612/3eecdedc6c54489589f75c043e297f5a/5f4431cc3c6f4e7198a3e9664cca766d.jpg, createdBy=600c102391, createdName=zhanghenhao, createdTime=Sun Apr 05 00:00:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211371, encodeId=290812113e1ba, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：投了一篇纯细胞的实验，中午投下午就拒了，说是内容不符合本杂志，效率还是很高的，没有耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Fri Apr 15 09:52:38 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213196, encodeId=d9ed12131966e, content=这个期刊不能有共同一作吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7c85517273, createdName=shyhxyxz1005, createdTime=Thu Apr 21 16:14:18 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218878, encodeId=c5bf12188e816, content=接受临床病例分析么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d088154040, createdName=ms3000001846552432, createdTime=Wed May 11 22:01:48 CST 2022, time=2022-05-11, status=1, ipAttribution=)]
    2025-06-12 匿名用户

    邮箱投稿

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2269047, encodeId=1f75226904e6e, content=邮箱投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:45:59 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2269044, encodeId=56052269044a8, content=40美元审稿费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:20:30 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801294, encodeId=4aaa80129474, content=投了三个多月，中间催了两次，说在under review，现在仍然没有消息，这是什么鬼啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 05 10:55:30 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121989, encodeId=04fe21219896b, content=这个杂志的文章怎么都没有doi啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d02d8107809, createdName=ms9000000001550341, createdTime=Sun Mar 26 23:07:49 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2110877, encodeId=b1dc21108e700, content=这个杂志的投稿链接是哪里啊？找半天找不到。。。，有哪位大神知道，指点指点一下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70614861774, createdName=shengbin117, createdTime=Thu Jan 19 19:38:39 CST 2023, time=2023-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1220227, encodeId=7e7d122022e64, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：免疫;肿瘤;基础<br>经验分享：已投被拒，建议投更专业的杂志，婉拒吧，挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Tue May 17 09:54:10 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588195, encodeId=bd50588195c8, content=说研究内容陈旧，前言里有一句话说法是错的，感觉审稿人很不正规。但是人家的退稿意见倒是做成很正式的感觉:官方的logo，还做成像一封信的样子的附件。。。我是该高兴呢，还是高兴呢？<span class="quote">海上飘星 2020-03-16 00:00:00 发表:<br>有什么审稿意见吗？谢谢。</span>, beContent=海上飘星 2020-03-16 00:00:00 发表: 有什么审稿意见吗？谢谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230612/3eecdedc6c54489589f75c043e297f5a/5f4431cc3c6f4e7198a3e9664cca766d.jpg, createdBy=600c102391, createdName=zhanghenhao, createdTime=Sun Apr 05 00:00:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211371, encodeId=290812113e1ba, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：投了一篇纯细胞的实验，中午投下午就拒了，说是内容不符合本杂志，效率还是很高的，没有耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Fri Apr 15 09:52:38 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213196, encodeId=d9ed12131966e, content=这个期刊不能有共同一作吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7c85517273, createdName=shyhxyxz1005, createdTime=Thu Apr 21 16:14:18 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218878, encodeId=c5bf12188e816, content=接受临床病例分析么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d088154040, createdName=ms3000001846552432, createdTime=Wed May 11 22:01:48 CST 2022, time=2022-05-11, status=1, ipAttribution=)]
    2025-06-12 匿名用户

    40美元审稿费

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2269047, encodeId=1f75226904e6e, content=邮箱投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:45:59 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2269044, encodeId=56052269044a8, content=40美元审稿费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:20:30 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801294, encodeId=4aaa80129474, content=投了三个多月，中间催了两次，说在under review，现在仍然没有消息，这是什么鬼啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 05 10:55:30 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121989, encodeId=04fe21219896b, content=这个杂志的文章怎么都没有doi啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d02d8107809, createdName=ms9000000001550341, createdTime=Sun Mar 26 23:07:49 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2110877, encodeId=b1dc21108e700, content=这个杂志的投稿链接是哪里啊？找半天找不到。。。，有哪位大神知道，指点指点一下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70614861774, createdName=shengbin117, createdTime=Thu Jan 19 19:38:39 CST 2023, time=2023-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1220227, encodeId=7e7d122022e64, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：免疫;肿瘤;基础<br>经验分享：已投被拒，建议投更专业的杂志，婉拒吧，挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Tue May 17 09:54:10 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588195, encodeId=bd50588195c8, content=说研究内容陈旧，前言里有一句话说法是错的，感觉审稿人很不正规。但是人家的退稿意见倒是做成很正式的感觉:官方的logo，还做成像一封信的样子的附件。。。我是该高兴呢，还是高兴呢？<span class="quote">海上飘星 2020-03-16 00:00:00 发表:<br>有什么审稿意见吗？谢谢。</span>, beContent=海上飘星 2020-03-16 00:00:00 发表: 有什么审稿意见吗？谢谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230612/3eecdedc6c54489589f75c043e297f5a/5f4431cc3c6f4e7198a3e9664cca766d.jpg, createdBy=600c102391, createdName=zhanghenhao, createdTime=Sun Apr 05 00:00:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211371, encodeId=290812113e1ba, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：投了一篇纯细胞的实验，中午投下午就拒了，说是内容不符合本杂志，效率还是很高的，没有耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Fri Apr 15 09:52:38 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213196, encodeId=d9ed12131966e, content=这个期刊不能有共同一作吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7c85517273, createdName=shyhxyxz1005, createdTime=Thu Apr 21 16:14:18 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218878, encodeId=c5bf12188e816, content=接受临床病例分析么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d088154040, createdName=ms3000001846552432, createdTime=Wed May 11 22:01:48 CST 2022, time=2022-05-11, status=1, ipAttribution=)]
    2020-07-05 海上飘星

    投了三个多月，中间催了两次，说在under review，现在仍然没有消息，这是什么鬼啊？

    12

    展开12条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2269047, encodeId=1f75226904e6e, content=邮箱投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:45:59 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2269044, encodeId=56052269044a8, content=40美元审稿费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:20:30 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801294, encodeId=4aaa80129474, content=投了三个多月，中间催了两次，说在under review，现在仍然没有消息，这是什么鬼啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 05 10:55:30 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121989, encodeId=04fe21219896b, content=这个杂志的文章怎么都没有doi啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d02d8107809, createdName=ms9000000001550341, createdTime=Sun Mar 26 23:07:49 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2110877, encodeId=b1dc21108e700, content=这个杂志的投稿链接是哪里啊？找半天找不到。。。，有哪位大神知道，指点指点一下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70614861774, createdName=shengbin117, createdTime=Thu Jan 19 19:38:39 CST 2023, time=2023-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1220227, encodeId=7e7d122022e64, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：免疫;肿瘤;基础<br>经验分享：已投被拒，建议投更专业的杂志，婉拒吧，挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Tue May 17 09:54:10 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588195, encodeId=bd50588195c8, content=说研究内容陈旧，前言里有一句话说法是错的，感觉审稿人很不正规。但是人家的退稿意见倒是做成很正式的感觉:官方的logo，还做成像一封信的样子的附件。。。我是该高兴呢，还是高兴呢？<span class="quote">海上飘星 2020-03-16 00:00:00 发表:<br>有什么审稿意见吗？谢谢。</span>, beContent=海上飘星 2020-03-16 00:00:00 发表: 有什么审稿意见吗？谢谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230612/3eecdedc6c54489589f75c043e297f5a/5f4431cc3c6f4e7198a3e9664cca766d.jpg, createdBy=600c102391, createdName=zhanghenhao, createdTime=Sun Apr 05 00:00:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211371, encodeId=290812113e1ba, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：投了一篇纯细胞的实验，中午投下午就拒了，说是内容不符合本杂志，效率还是很高的，没有耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Fri Apr 15 09:52:38 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213196, encodeId=d9ed12131966e, content=这个期刊不能有共同一作吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7c85517273, createdName=shyhxyxz1005, createdTime=Thu Apr 21 16:14:18 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218878, encodeId=c5bf12188e816, content=接受临床病例分析么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d088154040, createdName=ms3000001846552432, createdTime=Wed May 11 22:01:48 CST 2022, time=2022-05-11, status=1, ipAttribution=)]
    2023-03-26 ms9000000001550341 来自浙江省

    这个杂志的文章怎么都没有doi啊？

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2269047, encodeId=1f75226904e6e, content=邮箱投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:45:59 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2269044, encodeId=56052269044a8, content=40美元审稿费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:20:30 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801294, encodeId=4aaa80129474, content=投了三个多月，中间催了两次，说在under review，现在仍然没有消息，这是什么鬼啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 05 10:55:30 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121989, encodeId=04fe21219896b, content=这个杂志的文章怎么都没有doi啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d02d8107809, createdName=ms9000000001550341, createdTime=Sun Mar 26 23:07:49 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2110877, encodeId=b1dc21108e700, content=这个杂志的投稿链接是哪里啊？找半天找不到。。。，有哪位大神知道，指点指点一下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70614861774, createdName=shengbin117, createdTime=Thu Jan 19 19:38:39 CST 2023, time=2023-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1220227, encodeId=7e7d122022e64, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：免疫;肿瘤;基础<br>经验分享：已投被拒，建议投更专业的杂志，婉拒吧，挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Tue May 17 09:54:10 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588195, encodeId=bd50588195c8, content=说研究内容陈旧，前言里有一句话说法是错的，感觉审稿人很不正规。但是人家的退稿意见倒是做成很正式的感觉:官方的logo，还做成像一封信的样子的附件。。。我是该高兴呢，还是高兴呢？<span class="quote">海上飘星 2020-03-16 00:00:00 发表:<br>有什么审稿意见吗？谢谢。</span>, beContent=海上飘星 2020-03-16 00:00:00 发表: 有什么审稿意见吗？谢谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230612/3eecdedc6c54489589f75c043e297f5a/5f4431cc3c6f4e7198a3e9664cca766d.jpg, createdBy=600c102391, createdName=zhanghenhao, createdTime=Sun Apr 05 00:00:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211371, encodeId=290812113e1ba, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：投了一篇纯细胞的实验，中午投下午就拒了，说是内容不符合本杂志，效率还是很高的，没有耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Fri Apr 15 09:52:38 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213196, encodeId=d9ed12131966e, content=这个期刊不能有共同一作吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7c85517273, createdName=shyhxyxz1005, createdTime=Thu Apr 21 16:14:18 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218878, encodeId=c5bf12188e816, content=接受临床病例分析么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d088154040, createdName=ms3000001846552432, createdTime=Wed May 11 22:01:48 CST 2022, time=2022-05-11, status=1, ipAttribution=)]
    2023-01-19 shengbin117 来自江苏省

    这个杂志的投稿链接是哪里啊？找半天找不到。。。，有哪位大神知道，指点指点一下，谢谢

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2269047, encodeId=1f75226904e6e, content=邮箱投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:45:59 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2269044, encodeId=56052269044a8, content=40美元审稿费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:20:30 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801294, encodeId=4aaa80129474, content=投了三个多月，中间催了两次，说在under review，现在仍然没有消息，这是什么鬼啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 05 10:55:30 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121989, encodeId=04fe21219896b, content=这个杂志的文章怎么都没有doi啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d02d8107809, createdName=ms9000000001550341, createdTime=Sun Mar 26 23:07:49 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2110877, encodeId=b1dc21108e700, content=这个杂志的投稿链接是哪里啊？找半天找不到。。。，有哪位大神知道，指点指点一下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70614861774, createdName=shengbin117, createdTime=Thu Jan 19 19:38:39 CST 2023, time=2023-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1220227, encodeId=7e7d122022e64, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：免疫;肿瘤;基础<br>经验分享：已投被拒，建议投更专业的杂志，婉拒吧，挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Tue May 17 09:54:10 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588195, encodeId=bd50588195c8, content=说研究内容陈旧，前言里有一句话说法是错的，感觉审稿人很不正规。但是人家的退稿意见倒是做成很正式的感觉:官方的logo，还做成像一封信的样子的附件。。。我是该高兴呢，还是高兴呢？<span class="quote">海上飘星 2020-03-16 00:00:00 发表:<br>有什么审稿意见吗？谢谢。</span>, beContent=海上飘星 2020-03-16 00:00:00 发表: 有什么审稿意见吗？谢谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230612/3eecdedc6c54489589f75c043e297f5a/5f4431cc3c6f4e7198a3e9664cca766d.jpg, createdBy=600c102391, createdName=zhanghenhao, createdTime=Sun Apr 05 00:00:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211371, encodeId=290812113e1ba, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：投了一篇纯细胞的实验，中午投下午就拒了，说是内容不符合本杂志，效率还是很高的，没有耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Fri Apr 15 09:52:38 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213196, encodeId=d9ed12131966e, content=这个期刊不能有共同一作吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7c85517273, createdName=shyhxyxz1005, createdTime=Thu Apr 21 16:14:18 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218878, encodeId=c5bf12188e816, content=接受临床病例分析么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d088154040, createdName=ms3000001846552432, createdTime=Wed May 11 22:01:48 CST 2022, time=2022-05-11, status=1, ipAttribution=)]
    2022-05-17 ms5000001157259702

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向：免疫;肿瘤;基础
    经验分享：已投被拒，建议投更专业的杂志，婉拒吧，挺快的

    2

    展开2条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2269047, encodeId=1f75226904e6e, content=邮箱投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:45:59 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2269044, encodeId=56052269044a8, content=40美元审稿费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:20:30 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801294, encodeId=4aaa80129474, content=投了三个多月，中间催了两次，说在under review，现在仍然没有消息，这是什么鬼啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 05 10:55:30 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121989, encodeId=04fe21219896b, content=这个杂志的文章怎么都没有doi啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d02d8107809, createdName=ms9000000001550341, createdTime=Sun Mar 26 23:07:49 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2110877, encodeId=b1dc21108e700, content=这个杂志的投稿链接是哪里啊？找半天找不到。。。，有哪位大神知道，指点指点一下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70614861774, createdName=shengbin117, createdTime=Thu Jan 19 19:38:39 CST 2023, time=2023-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1220227, encodeId=7e7d122022e64, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：免疫;肿瘤;基础<br>经验分享：已投被拒，建议投更专业的杂志，婉拒吧，挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Tue May 17 09:54:10 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588195, encodeId=bd50588195c8, content=说研究内容陈旧，前言里有一句话说法是错的，感觉审稿人很不正规。但是人家的退稿意见倒是做成很正式的感觉:官方的logo，还做成像一封信的样子的附件。。。我是该高兴呢，还是高兴呢？<span class="quote">海上飘星 2020-03-16 00:00:00 发表:<br>有什么审稿意见吗？谢谢。</span>, beContent=海上飘星 2020-03-16 00:00:00 发表: 有什么审稿意见吗？谢谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230612/3eecdedc6c54489589f75c043e297f5a/5f4431cc3c6f4e7198a3e9664cca766d.jpg, createdBy=600c102391, createdName=zhanghenhao, createdTime=Sun Apr 05 00:00:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211371, encodeId=290812113e1ba, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：投了一篇纯细胞的实验，中午投下午就拒了，说是内容不符合本杂志，效率还是很高的，没有耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Fri Apr 15 09:52:38 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213196, encodeId=d9ed12131966e, content=这个期刊不能有共同一作吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7c85517273, createdName=shyhxyxz1005, createdTime=Thu Apr 21 16:14:18 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218878, encodeId=c5bf12188e816, content=接受临床病例分析么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d088154040, createdName=ms3000001846552432, createdTime=Wed May 11 22:01:48 CST 2022, time=2022-05-11, status=1, ipAttribution=)]
    2020-04-05 zhanghenhao

    说研究内容陈旧，前言里有一句话说法是错的，感觉审稿人很不正规。但是人家的退稿意见倒是做成很正式的感觉:官方的logo，还做成像一封信的样子的附件。。。我是该高兴呢，还是高兴呢？海上飘星 2020-03-16 00:00:00 发表:
    有什么审稿意见吗？谢谢。

    海上飘星 2020-03-16 00:00:00 发表: 有什么审稿意见吗？谢谢。

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2269047, encodeId=1f75226904e6e, content=邮箱投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:45:59 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2269044, encodeId=56052269044a8, content=40美元审稿费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:20:30 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801294, encodeId=4aaa80129474, content=投了三个多月，中间催了两次，说在under review，现在仍然没有消息，这是什么鬼啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 05 10:55:30 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121989, encodeId=04fe21219896b, content=这个杂志的文章怎么都没有doi啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d02d8107809, createdName=ms9000000001550341, createdTime=Sun Mar 26 23:07:49 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2110877, encodeId=b1dc21108e700, content=这个杂志的投稿链接是哪里啊？找半天找不到。。。，有哪位大神知道，指点指点一下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70614861774, createdName=shengbin117, createdTime=Thu Jan 19 19:38:39 CST 2023, time=2023-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1220227, encodeId=7e7d122022e64, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：免疫;肿瘤;基础<br>经验分享：已投被拒，建议投更专业的杂志，婉拒吧，挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Tue May 17 09:54:10 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588195, encodeId=bd50588195c8, content=说研究内容陈旧，前言里有一句话说法是错的，感觉审稿人很不正规。但是人家的退稿意见倒是做成很正式的感觉:官方的logo，还做成像一封信的样子的附件。。。我是该高兴呢，还是高兴呢？<span class="quote">海上飘星 2020-03-16 00:00:00 发表:<br>有什么审稿意见吗？谢谢。</span>, beContent=海上飘星 2020-03-16 00:00:00 发表: 有什么审稿意见吗？谢谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230612/3eecdedc6c54489589f75c043e297f5a/5f4431cc3c6f4e7198a3e9664cca766d.jpg, createdBy=600c102391, createdName=zhanghenhao, createdTime=Sun Apr 05 00:00:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211371, encodeId=290812113e1ba, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：投了一篇纯细胞的实验，中午投下午就拒了，说是内容不符合本杂志，效率还是很高的，没有耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Fri Apr 15 09:52:38 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213196, encodeId=d9ed12131966e, content=这个期刊不能有共同一作吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7c85517273, createdName=shyhxyxz1005, createdTime=Thu Apr 21 16:14:18 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218878, encodeId=c5bf12188e816, content=接受临床病例分析么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d088154040, createdName=ms3000001846552432, createdTime=Wed May 11 22:01:48 CST 2022, time=2022-05-11, status=1, ipAttribution=)]
    2022-04-15 ms5000001157259702

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向：肿瘤
    经验分享：投了一篇纯细胞的实验，中午投下午就拒了，说是内容不符合本杂志，效率还是很高的，没有耽误时间

    4

    展开4条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2269047, encodeId=1f75226904e6e, content=邮箱投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:45:59 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2269044, encodeId=56052269044a8, content=40美元审稿费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:20:30 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801294, encodeId=4aaa80129474, content=投了三个多月，中间催了两次，说在under review，现在仍然没有消息，这是什么鬼啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 05 10:55:30 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121989, encodeId=04fe21219896b, content=这个杂志的文章怎么都没有doi啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d02d8107809, createdName=ms9000000001550341, createdTime=Sun Mar 26 23:07:49 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2110877, encodeId=b1dc21108e700, content=这个杂志的投稿链接是哪里啊？找半天找不到。。。，有哪位大神知道，指点指点一下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70614861774, createdName=shengbin117, createdTime=Thu Jan 19 19:38:39 CST 2023, time=2023-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1220227, encodeId=7e7d122022e64, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：免疫;肿瘤;基础<br>经验分享：已投被拒，建议投更专业的杂志，婉拒吧，挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Tue May 17 09:54:10 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588195, encodeId=bd50588195c8, content=说研究内容陈旧，前言里有一句话说法是错的，感觉审稿人很不正规。但是人家的退稿意见倒是做成很正式的感觉:官方的logo，还做成像一封信的样子的附件。。。我是该高兴呢，还是高兴呢？<span class="quote">海上飘星 2020-03-16 00:00:00 发表:<br>有什么审稿意见吗？谢谢。</span>, beContent=海上飘星 2020-03-16 00:00:00 发表: 有什么审稿意见吗？谢谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230612/3eecdedc6c54489589f75c043e297f5a/5f4431cc3c6f4e7198a3e9664cca766d.jpg, createdBy=600c102391, createdName=zhanghenhao, createdTime=Sun Apr 05 00:00:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211371, encodeId=290812113e1ba, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：投了一篇纯细胞的实验，中午投下午就拒了，说是内容不符合本杂志，效率还是很高的，没有耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Fri Apr 15 09:52:38 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213196, encodeId=d9ed12131966e, content=这个期刊不能有共同一作吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7c85517273, createdName=shyhxyxz1005, createdTime=Thu Apr 21 16:14:18 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218878, encodeId=c5bf12188e816, content=接受临床病例分析么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d088154040, createdName=ms3000001846552432, createdTime=Wed May 11 22:01:48 CST 2022, time=2022-05-11, status=1, ipAttribution=)]
    2022-04-21 shyhxyxz1005

    这个期刊不能有共同一作吗？

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2269047, encodeId=1f75226904e6e, content=邮箱投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:45:59 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2269044, encodeId=56052269044a8, content=40美元审稿费, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Thu Jun 12 13:20:30 CST 2025, time=2025-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801294, encodeId=4aaa80129474, content=投了三个多月，中间催了两次，说在under review，现在仍然没有消息，这是什么鬼啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=197, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150928/IMG5608CD12CF3009910.jpg, createdBy=2e761652994, createdName=海上飘星, createdTime=Sun Jul 05 10:55:30 CST 2020, time=2020-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2121989, encodeId=04fe21219896b, content=这个杂志的文章怎么都没有doi啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d02d8107809, createdName=ms9000000001550341, createdTime=Sun Mar 26 23:07:49 CST 2023, time=2023-03-26, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2110877, encodeId=b1dc21108e700, content=这个杂志的投稿链接是哪里啊？找半天找不到。。。，有哪位大神知道，指点指点一下，谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70614861774, createdName=shengbin117, createdTime=Thu Jan 19 19:38:39 CST 2023, time=2023-01-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1220227, encodeId=7e7d122022e64, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：免疫;肿瘤;基础<br>经验分享：已投被拒，建议投更专业的杂志，婉拒吧，挺快的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Tue May 17 09:54:10 CST 2022, time=2022-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588195, encodeId=bd50588195c8, content=说研究内容陈旧，前言里有一句话说法是错的，感觉审稿人很不正规。但是人家的退稿意见倒是做成很正式的感觉:官方的logo，还做成像一封信的样子的附件。。。我是该高兴呢，还是高兴呢？<span class="quote">海上飘星 2020-03-16 00:00:00 发表:<br>有什么审稿意见吗？谢谢。</span>, beContent=海上飘星 2020-03-16 00:00:00 发表: 有什么审稿意见吗？谢谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230612/3eecdedc6c54489589f75c043e297f5a/5f4431cc3c6f4e7198a3e9664cca766d.jpg, createdBy=600c102391, createdName=zhanghenhao, createdTime=Sun Apr 05 00:00:00 CST 2020, time=2020-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211371, encodeId=290812113e1ba, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：肿瘤<br>经验分享：投了一篇纯细胞的实验，中午投下午就拒了，说是内容不符合本杂志，效率还是很高的，没有耽误时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=84f05623291, createdName=ms5000001157259702, createdTime=Fri Apr 15 09:52:38 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213196, encodeId=d9ed12131966e, content=这个期刊不能有共同一作吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7c85517273, createdName=shyhxyxz1005, createdTime=Thu Apr 21 16:14:18 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1218878, encodeId=c5bf12188e816, content=接受临床病例分析么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d088154040, createdName=ms3000001846552432, createdTime=Wed May 11 22:01:48 CST 2022, time=2022-05-11, status=1, ipAttribution=)]
    2022-05-11 ms3000001846552432

    接受临床病例分析么

    0

共88条页码: 1/9页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分